This resulted in an increased NK cell activation (CD69, NKp30, NKp44, NKG2D) as well as an increased tumor-directed cytotoxicity against chronic myeloid leukemia (CML) blasts and the leukemia cell line K562 compared to those NK cells stimulated without slanMo (63, 65). Here, NCR2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.